Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Post by freedom2020on Aug 20, 2015 8:46pm

262 Views

Post# 24038200

PBI-4050 for IPF

If preliminary phase2/3 results are optimal prometic could apply for "fast track designation" from the FDA. The 2 newest approved IPF drugs "Esbriet (pirfenidone) and Ofev (nintedanib)" were fast tracked so I think if all goes well we might get fast tracked too.

Sourced from the FDA site:

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418991.htm

Bullboard Posts

Unique Battery Metals opportunity in Quebec